San Francisco, CA – June 1, 2022 – SamaCare, a prior authorization platform for physician-administered medications, today announced the close of a $12 million Series A funding round led by Clearlake Capital-backed Vive CollectiveTM, with participation from existing investors including NextView Ventures, South Park Commons, and Susa Capital. As part of the investment, Vive’s Founder and CEO Cheryl Cheng will join the company’s board of directors. The funding and partnership will enable SamaCare to expand practice penetration across existing and new specialties, ramp up customer acquisition and support for pharmaceutical manufacturers, and bring on key executives.
SamaCare offers retina, oncology, neurology, and rheumatology practices a unified prior authorization, enrollment, and benefits verification portal experience for specialty medication across payers. Currently, over 2,300 prescribers utilize SamaCare.
“We are excited to leverage the digital health and healthcare infrastructure expertise of Cheryl and the Vive CollectiveTM team as we continue to expand SamaCare’s penetration across retina and oncology practices, establish a strong foothold with neurology and rheumatology practices, and deepen our pharmaceutical company relationships,”said Syam Palakurthy, Founder and CEO of SamaCare.
SamaCare works with pharmaceutical manufacturers to help market access and patient services teams ensure that patients get access to therapeutics. SamaCare provides aggregate insights on barriers to access as well as a channel to empower pharma access teams at the point of care.
“SamaCare streamlines administrative processes that often impact patient care, and its platform can improve the patient experience, administrative efficiency, and even clinical outcomes by preventing unnecessary delays to care,”said Ms. Cheng. “SamaCare also offers biopharma partners unique insights in a normally opaque and hard to aggregate industry. We look forward to working closely with Syam and the entire SamaCare team to help expand its presence and reach to more patients.”